A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide

$30.00

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Psychopharmacology Bulletin, VOL 54 No. 1 Articles - 2024 Tags: intranasal, ketamine, Kimberly F. Farrand, mdd, michael-e-thase, open label, racemic, suicide, Timothy Whitaker

Description

Description

Original Research

A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide

By Timothy Whitaker, Kimberly F. Farrand, Michael E. Thase

A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide

Description

Original Research

Robert MA Hirschfeld, MD: Defining the Clinical Course of Bipolar Disorder: Response, Remission, Relapse, Recurrence, and Roughening

A Systematic Review of Augmentation Strategies for Major Depressive Disorder

Comparing the Methods Used to Compare Antidepressants

Remission as the Critical Outcome of Depression Treatment

A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide

Description

Original Research

Related products

Robert MA Hirschfeld, MD: Defining the Clinical Course of Bipolar Disorder: Response, Remission, Relapse, Recurrence, and Roughening

A Systematic Review of Augmentation Strategies for Major Depressive Disorder

Comparing the Methods Used to Compare Antidepressants

Remission as the Critical Outcome of Depression Treatment